TheStreet Biotech

News affecting the biotech industry and associated stocks. Includes #biotech trends, market analysis as well as mergers and acquisition news. cc: @TheStreet

[TheStreet Biotech @TSTbiotech]

New home for @TheStreet's #biotech news. Includes trends, market analysis as well as mergers and acquisition news.

[TheStreet Biotech @TSTbiotech]

Celgene, Agios Expand, Amend Cancer Drug Partnership https://t.co/cJNhocyZG1

[TheStreet Biotech @TSTbiotech]

Heron and the never-ending FDA drug review https://t.co/WNvxNAZlfE

[TheStreet Biotech @TSTbiotech]

Heron and the never-ending FDA drug review https://t.co/WsJP05D0sJ

[TheStreet Biotech @TSTbiotech]

Celgene, Agios Expand, Amend Cancer Drug Partnership https://t.co/sG2ECiQjBz

[TheStreet Biotech @TSTbiotech]

Investors comforted as Perrigo sticks to forecast https://t.co/JKPxJXMa8k

[TheStreet Biotech @TSTbiotech]

$REGN spike not tied to $PFE's $ANAC deal, but it doesn't hurt https://t.co/38VRanR0Ak

[TheStreet Biotech @TSTbiotech]

Pfizer beats Allergan to excema-drugmaker Anacor for $5.2B https://t.co/sfE55cl0u8

[TheStreet Biotech @TSTbiotech]

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study https://t.co/vaFBsYZm2S

[TheStreet Biotech @TSTbiotech]

Pfizer Buying Anacor in $5.2 Billion Cash Deal https://t.co/vLfeoU50kX

[TheStreet Biotech @TSTbiotech]

$MDVN shares stand pat amid further bid speculation https://t.co/hsDIAVR89N

[TheStreet Biotech @TSTbiotech]

$MYL tacks on another generics company on the cheap https://t.co/REK9XOgPKM

[TheStreet Biotech @TSTbiotech]

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk should not be trusted $XON https://t.co/a4qhIFfjQq

[TheStreet Biotech @TSTbiotech]

New regime at $PRGO provides reason to invest https://t.co/4Vrb4S5xID

[TheStreet Biotech @TSTbiotech]

Cramer says buy $DOW & $DD over $MON in seed business https://t.co/Pr0biRQWpx

[TheStreet Biotech @TSTbiotech]

Mast (mstx) sickle cell drug seeks to defy long odds like leicester city https://t.co/nHPZmcEfvt

[TheStreet Biotech @TSTbiotech]

DOJ investigation has little impact on pharmas' share prices https://t.co/bjYWTjDCz0

[TheStreet Biotech @TSTbiotech]

Global bidding war seen for Medivation https://t.co/YeoDLGXTcT

[TheStreet Biotech @TSTbiotech]

Cramer sees more upside in $AGN https://t.co/86qHcoSY23

[TheStreet Biotech @TSTbiotech]

$AGN authorizes $10 billion buy back, beats estimates https://t.co/j3YHGrMB40

[TheStreet Biotech @TSTbiotech]

CytRx bear thesis explained: why sarcoma drug trial will fail https://t.co/vXRYPdz1CU